LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanoparticle-Based System Developed for Delivery of CRISPR/Cas9

By LabMedica International staff writers
Posted on 30 Nov 2017
Image: Investigators have developed nanoparticles that can transport the CRISPR genome-editing system in vivo and specifically modify genes, eliminating the need to use viruses for delivery (Photo courtesy of Massachusetts Institute of Technology).
Image: Investigators have developed nanoparticles that can transport the CRISPR genome-editing system in vivo and specifically modify genes, eliminating the need to use viruses for delivery (Photo courtesy of Massachusetts Institute of Technology).
A novel nanoparticle transport system was used to deliver the CRISPR/Cas9 genome editing tool into liver cells of living mice, which caused silencing of a specific enzyme and significant lowering of cholesterol levels.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand. Efficient genome editing with Cas9-sgRNA in vivo has required the use of viral delivery systems, which have limitations for clinical applications.

To bypass the need for a viral carrier, investigators at the Massachusetts Institute of Technology (Cambridge, USA) identified regions of sgRNA that could be modified while maintaining or enhancing genome-editing activity. They then developed an optimal set of chemical modifications for in vivo applications.

The investigators reported in the November 13, 2017, online edition of the journal Nature Biotechnology that by using lipid nanoparticle formulations of these enhanced sgRNAs and mRNA encoding Cas9, they were able to show that a single intravenous injection of this mixture into mice induced specific editing of the enzyme Pcsk9 (Proprotein convertase subtilisin/kexin type 9) in the livers of more than 80% of the treated animals. Serum Pcsk9 was reduced to undetectable levels, and cholesterol levels were significantly lowered by about 35 to 40% in these animals.

"What is really exciting here is that we have shown you can make a nanoparticle that can be used to permanently and specifically edit the DNA in the liver of an adult animal," said senior author Dr. Daniel Anderson, associate professor of chemical engineering at the Massachusetts Institute of Technology.

Related Links:
Massachusetts Institute of Technology

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more